HFCWO devices market seen rising to $3.77 billion by 2030

The market for high-frequency chest-wall oscillation devices is projected to climb from $2.65 billion in 2025 to $3.77 billion by 2030, driven by rising respiratory disease burden, home-care adoption and broader use in airway clearance therapy. North America leads the market now, while Asia-Pacific is expected to grow fastest.

Why it matters: - High-frequency chest-wall oscillation devices are used to clear mucus from the lungs and support people with chronic respiratory disease. - Rising COPD, cystic fibrosis and other chronic lung conditions are expanding demand for non-invasive respiratory care. - The forecast points to continued growth in hospital, home-health and outpatient settings through 2030.

What happened: - The Business Research Company released an outlook for the high-frequency chest-wall oscillation devices market. - The market is projected to grow from $2.65 billion in 2025 to $2.86 billion in 2026. - The report forecasts the market will reach $3.77 billion by 2030. - The report also projects an 8.0% CAGR for 2025-2026 and 7.2% CAGR for 2026-2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - HFCWO devices deliver mechanical vibrations to the chest wall to loosen mucus and help remove it from the lungs. - The devices are used as airway clearance therapy and are intended to improve breathing function. - Growth in the market has been supported by rising chronic respiratory disease rates, wider hospital adoption of airway clearance therapies and stronger respiratory care infrastructure. - The report points to a growing elderly population with respiratory conditions, more demand for home healthcare devices and more cases of cystic fibrosis and bronchiectasis. - The report also cites expansion in outpatient respiratory care services and a stronger focus on long-term respiratory disease management. - Key trends include broader adoption of home-based airway clearance therapies, demand for portable and wearable devices, and more use in pediatric and geriatric care. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here. - The 2026 report package adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, and updated graphics and tables.

Between the lines: - COPD is a major driver because the condition creates ongoing mucus-management needs and higher infection risk. - The Australian Institute of Health and Welfare reported in June 2024 that COPD accounted for 3.6% of total disease burden in 2023 and 4% of all deaths in 2022, or 7,691 fatalities. - The European Environment Agency said in November 2024 that chronic respiratory diseases were the third leading cause of death across EEA countries and accounted for more than 60% of nearly 420,000 annual fatalities. - The regional split suggests mature demand in North America and faster adoption potential in Asia-Pacific as healthcare access expands.

What's next: - Demand is expected to rise as home healthcare, portable devices and outpatient respiratory care gain share. - Market growth should continue as aging populations and chronic lung disease prevalence increase worldwide. - Manufacturers will likely keep targeting non-invasive therapy formats and broader patient segments, including pediatric and geriatric users.

The bottom line: - HFCWO devices are moving from a niche respiratory support tool toward broader use in chronic care, and the market outlook points to steady expansion through 2030.